A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

51 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-04-30

Study Completion Date

2015-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open-label, multicenter clinical study in order to collect and examine data concerning the safety and efficacy of ruxolitinib in patients with Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Post-Essential Thrombocythemia (ET) MF.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

NCT01348490

MPN (Myeloproliferative Neoplasms)

COMPLETED PHASE2

Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis

NCT01445769

Primary Myelofibrosis Post-Polycythemia Vera Myelofibrosis Post-Essential Thrombocythemia Myelofibrosis

COMPLETED PHASE2

Ruxolitinib in Thrombocythemia and Polycythemia Vera

NCT04644211

Essential Thrombocythemia Polycythemia Vera

RECRUITING PHASE2

Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia

NCT00726232

Myeloproliferative Neoplasm (MPN)

TERMINATED PHASE2

Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

NCT04543279

Myelofibrosis Thrombocytopenia

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Myelofibrosis (MF)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ruxolitinib

Ruxolitinib was administered orally twice daily at the starting dose of 5 mg, 15 mg or 20 mg bid based on Baseline platelet counts. The dosage was subsequently adjusted for safety and efficacy so that each patient was titrated to their most appropriate dose.

Group Type EXPERIMENTAL

Ruxolitinib

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ruxolitinib

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. ≥18 years of age
2. Diagnosis of PMF, PPV-MF, or PET-MF, regardless of JAK2 mutational status. The diagnostic of PMF will be according to the World Health Organization (WHO) criteria (Thiele et al., 2008) and PPV-MF and PET-MF according to the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria (Barosi et al., 2008).
3. At least one risk factors provided in the definition of IWG-MRT (Cervantes et al., 2009; classified as intermediate risk-1, intermediate risk-2, or high risk)
4. Patients with intermediate risk-1 (patients who have only one of the IMG-MRT risk factors indicated above ) must have palpable splenomegaly with a length of ≥5 cm from the costal margin to the point of the greatest spleen protrusion.
5. Proportion of blasts in peripheral blood \<10%
6. ECOG performance status of 0 to 2
7. The following values for bone marrow function prior to treatment:

1. Absolute neutrophil count ≥1,000/μL, and
2. Platelet count ≥50,000/μL without administration of a growth factor, thrombopoietin, or platelet transfusion
8. Stem cell transplantation is not a treatment option at present because it is not indicated or because there are no suitable donors.
9. All drugs used to treat MF were discontinued at least 28 days before treatment initiation.
10. Informed consent form should be signed before any screening procedures is performed

Exclusion Criteria

1. Hepatic or renal impairment as indicated by the following:

* Direct bilirubin ≥2-fold than the upper limit of normal (ULN)
* Alanine aminotransferase (ALT) \>2.5-fold ULN
* Creatinine \>2.0 mg/dL
2. Clinically significant infection by bacteria, fungus, mycobacteria, parasite, or virus (screening and enrollment postponed until completion of antibiotic treatment in patients with an acute bacterial infection that requires antibiotic use)
3. Active hepatitis A, B, or C or HIV infection defined by a positive IgM-HA Ab test \[hepatitis A virus antibody (immunoglobulin M \[IgM\])\], HBs Ag test (hepatitis B surface antigen), HCV Ab test (hepatitis C virus antibody), or HIV Ab (human immunodeficiency virus antibody) at screening.
4. History of malignancy within the previous 3 years, except for early-stage squamous cell carcinoma and basal cell carcinoma.
5. History of serious congenital or acquired hemorrhagic disease
6. Previous platelet count \<25,000/μL or absolute neutrophil count \<500/μL, except for patients currently undergoing treatment for a myeloproliferative neoplasm or cytotoxic therapy for any other reason.
7. Splenic irradiation within 12 months before screening
8. Administration of hematopoietic growth factor receptor agonists (erythropoietin, granulocyte colony stimulating factor, romiplostim, eltrombopag) within 14 days before screening or 28 days before treatment initiation.
9. Currently receiving another investigational drug, or received another investigational drug within 30 days before the start of treatment.
10. History of myocardial infarction or acute coronary syndrome within 6 months before screening
11. Poorly controlled or unstable angina at present
12. Rapid or paroxysmal atrial fibrillation at present
13. Active alcohol or drug addiction that could hinder the patient's ability to comply with the study's requirements
14. Pregnant or currently breastfeeding woman
15. Women of childbearing potential or men with reproductive ability who are unwilling to take appropriate contraception measures
16. Patient with any concurrent condition that, in the Investigator's opinion, would jeopardize the safety of the patient or compliance with the protocol
17. History of hypersensitivity to the study drug or a drug with a similar chemical structure

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No